Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

 Roche Reports Results of Tecentriq in P-III IMagyn050 Study for Women with 1L Newly Diagnosed Advanced Stage Ovarian Cancer

https://www.pharmashots.com/14193/%EF%BB%BFroche-reports-results-of-ocrevus-ocrelizumab-in-three-p-iii-studies-for-relapsing-and-primary-progressive-multiple-sclerosis/

Shots:

  • The P-III IMagyn050 study involves assessing of Tecentriq + Avastin, paclitaxel, and carboplatin vs PBO + Avastin, paclitaxel and carboplatin in the ratio (1:1) in women with Stage III or IV ovarian cancer who are undergoing neoadjuvant or adjuvant therapy
  • The study did not meet its 1EP i.e. PFS while the safety data were consistent with the safety profile of the combination  
  • Tecentriq is a mAb targeting PD-L1 protein while blocking its interaction with PD-1 and B7.1 receptors. Additionally, Roche collaborated with The GOG Foundation and European Network of Gynaecological Oncological Trial groups (ENGOT) [ENGOT OV-39] to conduct P-III IMagyn050 Trial

Click here to read full press release/ article | Ref: Roche | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post